Testosterone deficiency (TD) therapy if prostate cancer

Testosterone therapy and prostate cancer

Testosterone therapy can be offered to men with symptomatic TD and treated localised low-risk prostate cancer (Gleason score <8, stages 1-2, preoperative prostate specific antigen (PSA) <10ng/mL), as long as it is not started before 1 year of follow-up and they have no evidence of active disease (based on measured PSA level, DRE result and absence of metastases).

Reference:

• 1. Dohle GH, Arver S, Bettochi C et al. Guidelines on Male Hypogonadism. European Association of Urology 2017. Available at: http://uroweb.org/guideline/male-hypogonadism/ (Accessed May 2018).